Phase II clinical study of RG3502 in HER2 positive breast cancer patients
Phase 2
- Conditions
- HER2 positive Breast Cancer
- Registration Number
- JPRN-jRCT2080221240
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Female
- Target Recruitment
- 70
Inclusion Criteria
Inoperable, locally advanced/recurrent or metastatic breast cancer
- HER2-positive (FISH + or IHC 3+)
- ECOG PS :0-2
Exclusion Criteria
- Clinically significant cardiac disease
- Grade 3 or higher Hypersensitivity to trastuzumab
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method